MedTrace Logo

HIV, Buprenorphine, and the Criminal Justice System

NCT01550341 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2020-05-06

Study results available
· View outcomes & findings →

Summary

The aims of STRIDE were changed as of July, 2014. The revised project, called STRIDE2, has a longitudinal, non-randomized, observational study design. The population under study consists of individuals living with HIV who are dependent on opioids.

Conditions

  • Human Immunodeficiency Virus
  • Acquired Immunodeficiency Syndrome
  • Opiate Addiction
  • Drug Dependence

Interventions

DRUG

Buprenorphine/naloxone

2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.

DRUG

Placebo Oral Tablet

2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.

Sponsors & Collaborators

  • George Mason University

    collaborator OTHER

  • Howard University

    collaborator OTHER

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • Yale University

    lead OTHER

Principal Investigators

  • Frederick Altice, MD · Yale University School of Medicine/AIDS Program

  • Faye Taxman, PhD · George Mason University

  • William Lawson, MD · Howard University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-23
Primary Completion
2015-11-30
Completion
2016-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01550341 on ClinicalTrials.gov